Geode Capital Management’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.1K | Sell |
3,276
-1,069
| -25% | -$10.3K | ﹤0.01% | 4328 |
|
|
2026
Q1 | $32.6K | Buy |
4,345
+614
| +16% | +$5.76K | ﹤0.01% | 4395 |
|
|
2025
Q4 | $32.8K | Hold |
3,731
| – | – | ﹤0.01% | 4311 |
|
|
2025
Q3 | $106K | Buy |
3,731
+31
| +0.8% | +$668 | ﹤0.01% | 4119 |
|
|
2025
Q2 | $49.4K | Buy |
3,700
+584
| +19% | +$6.42K | ﹤0.01% | 4219 |
|
|
2025
Q1 | $24.3K | Buy |
3,116
+218
| +8% | +$1.94K | ﹤0.01% | 4314 |
|
|
2024
Q4 | $22.2K | Sell |
2,898
-217
| -7% | -$4.95K | ﹤0.01% | 4372 |
|
|
2024
Q3 | $165K | Buy |
3,115
+60
| +2% | +$5.73K | ﹤0.01% | 3964 |
|
|
2024
Q2 | $363K | Buy |
3,055
+208
| +7% | +$28.3K | ﹤0.01% | 3690 |
|
|
2024
Q1 | $579K | Buy |
2,847
+745
| +35% | +$133K | ﹤0.01% | 3557 |
|
|
2023
Q4 | $341K | Sell |
2,102
-512
| -20% | -$86.7K | ﹤0.01% | 3747 |
|
|
2023
Q3 | $255K | Buy |
2,614
+2
| +0.1% | +$368 | ﹤0.01% | 3881 |
|
|
2023
Q2 | $705K | Buy |
2,612
+206
| +9% | +$72K | ﹤0.01% | 3487 |
|
|
2023
Q1 | $848K | Hold |
2,406
| – | – | ﹤0.01% | 3418 |
|
|
2022
Q4 | $902K | Buy |
2,406
+152
| +7% | +$75.8K | ﹤0.01% | 3389 |
|
|
2022
Q3 | $1.07M | Buy |
2,254
+186
| +9% | +$110K | ﹤0.01% | 3357 |
|
|
2022
Q2 | $1.23M | Sell |
2,068
-106
| -5% | -$60.6K | ﹤0.01% | 3328 |
|
|
2022
Q1 | $1.31M | Buy |
2,174
+58
| +3% | +$32K | ﹤0.01% | 3487 |
|
|
2021
Q4 | $1.6M | Buy |
2,116
+256
| +14% | +$205K | ﹤0.01% | 3478 |
|
|
2021
Q3 | $1.81M | Buy |
1,860
+101
| +6% | +$65.4K | ﹤0.01% | 3396 |
|
|
2021
Q2 | $1.02M | Buy |
1,759
+71
| +4% | +$45.8K | ﹤0.01% | 3586 |
|
|
2021
Q1 | $1.33M | Buy |
1,688
+193
| +13% | +$194K | ﹤0.01% | 3441 |
|
|
2020
Q4 | $1.52M | Buy |
1,495
+56
| +4% | +$38.9K | ﹤0.01% | 3214 |
|
|
2020
Q3 | $826K | Hold |
1,439
| – | – | ﹤0.01% | 3278 |
|
|
2020
Q2 | $834K | Hold |
1,439
| – | – | ﹤0.01% | 3200 |
|
|
2020
Q1 | $647K | Buy |
1,439
+281
| +24% | +$254K | ﹤0.01% | 3191 |
|
|
2019
Q4 | $1.97M | Buy |
1,158
+85
| +8% | +$73.9K | ﹤0.01% | 3013 |
|
|
2019
Q3 | $507K | Buy |
1,073
+163
| +18% | +$88.4K | ﹤0.01% | 3468 |
|
|
2019
Q2 | $584K | Hold |
910
| – | – | ﹤0.01% | 3409 |
|
|
2019
Q1 | $743K | Buy |
910
+368
| +68% | +$297K | ﹤0.01% | 3282 |
|
|
2018
Q4 | $242K | Hold |
542
| – | – | ﹤0.01% | 3616 |
|
|
2018
Q3 | $374K | Sell |
542
-3
| -0.6% | -$967 | ﹤0.01% | 3565 |
|
|
2018
Q2 | $177K | Sell |
545
-180
| -25% | -$78K | ﹤0.01% | 3753 |
|
|
2018
Q1 | $415K | Buy |
725
+19
| +3% | +$15.1K | ﹤0.01% | 3463 |
|
|
2017
Q4 | $613K | Buy |
706
+37
| +6% | +$35.7K | ﹤0.01% | 3283 |
|
|
2017
Q3 | $662K | Buy |
669
+9
| +1% | +$9.01K | ﹤0.01% | 3267 |
|
|
2017
Q2 | $836K | Buy |
+660
| New | +$1.33M | ﹤0.01% | 3172 |
|
Other funds holding MTNB
HIW
SIG
TRCT
Geode Capital Management's MTNB Position: Q2 2026 in Review
Geode Capital Management reduced its Matinas BioPharma (MTNB) stake by 25% in Q2 2026, selling an estimated $10.3K and leaving 3,276 shares worth $30.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4328.
Geode Capital Management first reported a position in MTNB in Q2 2017 and has held it in 37 quarters since. The position peaked at $1.97M in Q4 2019. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.
- Geode Capital Management held 3,276 shares of Matinas BioPharma worth $30.1K as of Q2 2026.
- Geode Capital Management sold 1,069 Matinas BioPharma shares in Q2 2026, an estimated $10.3K.
- Matinas BioPharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4328 holding.
- Geode Capital Management first reported a position in Matinas BioPharma in Q2 2017 and has held it in 37 quarters since.
- Geode Capital Management's Matinas BioPharma position peaked at $1.97M in Q4 2019.
- 23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.